Micromedic Technologies Ltd. is a publicly traded company listed on the Tel Aviv Stock Exchange. The Company focuses, through its investee companies, on the development and commercialization of novel molecular biomarkers related to cancer, including early detection of disease, genetic risk and optimization of treatment modalities (personalized medicine).
Micromedic has created collaborations & strategic alliances with leading research and clinical institutes in Israel and in the US. Present collaborations include the Hadassah Medical Center in Jerusalem, the Tel Aviv Sourasky Medical Center and the University of Florida, USA.
Micromedic’s Business Model is licensing commercialization rights from leading scientific institutes in Israel and abroad for research with a significant business potential and “translation” into a new product.
Micromedic’s Projects Include:
Zetiq - An Innovative Cell Staining Technology for the Detection of Cancer:
Zetiq is a daughter company developing a differential staining technology for the identification of cancerous cells, enabling, among others, carrying out screening tests for the detection of cancer (CellDetect®). The CellDetect® technology is aimed to assist in the identification of specific cell populations by staining them with a unique dye. This enables a quick and accurate identification of cancerous cells as well as monitoring the effect anti-cancerous therapeutics may have on them. CellDetect® has demonstrated proof of concept in the early identification and monitoring of cervical cancer and bladder cancer.
Bio-Mark – A Blood-Based Test for the Early Detection of Colorectal Cancer: Bio-Mark is a daughter company focusing on the development of a blood-based test for the early detection of colorectal cancer (CRC), already at the adenoma stage. The test is positioned to replace the fecal occult blood test (FOBT) which is the most common method currently used for screening average risk populations. The test under development will enable an accurate and user-friendly diagnosis of otherwise healthy populations that are recommended to undergo colonoscopy. The test is based on the oncogene CD24 and the research carried out by Prof. Nadir Arber of the Tel-Aviv Sourasky Medical Center.
Bio-Gene - Risk Assessment for Hereditary Breast and/or Ovarian Cancer: Bio-Gene is a daughter company developing a blood-based test for the identification of carriers of harmful mutations in BRCA genes, mutations that increase the risk of developing breast and/or ovarian cancer. The test is based on the research carried out by Prof. Tamar Peretz and Dr. Asher Salmon of the Hadassah Medical Center in Jerusalem.
BRONJ - Risk Assessment for the Development of Bisphosphonate Related Osteonecrosis of the Jaw: BRONJ, osteonecrosis of the jaw, is a devastating side effect resulting from the use of drugs of the bisphosphonate family. This phenomenon has been observed in multiple myeloma, prostate cancer and breast cancer patients treated with the IV form of the drug as well as in osteoporosis patients treated with the oral form. The project, which is based on research carried out by Dr. Josef Katz from the University of Florida, USA, focuses on the development of a unique genetic marker for patients that are at a higher risk for developing this side effect.
